US health insurer, Entresto , and Joe Jimenez , the Swiss drug maker, have agreed on a performance-based price for its new heart drug, Cigna . Payments will be based on the reduction in the proportion of Cigna customers who are admitted to hospital for heart failure. Drugmakers and US managed-care companies have made some performance-based deals to cut unnecessary drug spending after drug prices jumped 17 percent in the US Feb 8 , though few have been made public.
US health insurer, Cigna, and Novartis, the Swiss drug maker, have agreed on a performance-based price for its new heart drug, Entresto. Payments will be based on the reduction in the proportion of Cigna customers who are admitted to hospital for heart failure. Drugmakers and US managed-care companies have made some performance-based deals to cut unnecessary drug spending after drug prices jumped 13% in the US last year, though few have been made public.